Literature DB >> 18473708

Anti-obesity drugs.

Robert F Kushner1.   

Abstract

BACKGROUND: Recent discoveries about the metabolic and genetic control systems that govern regulation of body weight and energy expenditure have afforded the opportunity to develop pharmacological agents that can be used as adjunctive treatments for patients with obesity. However, the scarcity of medications available or those that have made it to Phase III trials reflects the difficult challenge of manipulating the biology of appetite regulation.
OBJECTIVE: The aim of this study was to inform health professionals about new anti-obesity medications that target neuronal systems within the central nervous system and peripheral humoral proteins that send signals to the central nervous system.
METHODS: A critical review was conducted of information available from the medical literature. RESULTS/
CONCLUSIONS: An emerging theme is to use combination therapies that are directed towards several targets or leverage existing gastrointestinal satiety hormonal signals. By using combination therapies, it is anticipated that greater weight loss will be achieved compared to monotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473708     DOI: 10.1517/14656566.9.8.1339

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

1.  An exciting challenge for obesity research in Italy: the role of the Journal of Endocrinological Investigation.

Authors:  R Pasquali; R Vettor; S Cinti
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

2.  Eating for life: designing foods for appetite control.

Authors:  Peter J Wilde
Journal:  J Diabetes Sci Technol       Date:  2009-03-01

3.  Pharmacotherapies for obesity: past, current, and future therapies.

Authors:  Lisa L Ioannides-Demos; Loretta Piccenna; John J McNeil
Journal:  J Obes       Date:  2010-12-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.